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Background: The environmental contribution to autism spectrum disorders (ASD) is largely unknown,
but household pesticides are receiving increased attention. We examined associations between ASD and
maternally-reported use of imidacloprid, a common flea and tick treatment for pets.
Methods: Bayesian logistic models were used to estimate the association between ASD and imidacloprid
and to correct for potential differential exposure misclassification due to recall in a case control study of ASD.
Results: Our analytic dataset included complete information for 262 typically developing controls and 407 children
with ASD. Compared with exposure among controls, the odds of prenatal imidacloprid exposure among children
with ASD were slightly higher, with an odds ratio (OR) of 1.3 (95% Credible Interval [CrI] 0.78, 2.2). A susceptibility
window analysis yielded higher ORs for exposures during pregnancy than for early life exposures, whereas
limiting to frequent users of imidacloprid, the OR increased to 2.0 (95% CI 1.0, 3.9).
Conclusions: Within plausible estimates of sensitivity and specificity, the association could result from exposure
misclassification alone. The association between imidacloprid exposure and ASD warrants further investigation,
and this work highlights the need for validation studies regarding prenatal exposures in ASD.
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Autism spectrum disorders (ASD) are a set of deve-
lopmental conditions characterized by a constellation of
impairments in social interaction and communication,
and repetitive patterns of interests or behaviors [1-4]. The
etiology of ASD is largely unknown. Prenatal and early life
exposures to pesticides have been of growing concern
in relation to birth outcomes and children’s neuro-
logic or neurocognitive development [5-13]. A few studies
have described associations between ASD and pesticides
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stated.Animal models have revealed that prenatal exposure to
the insecticide imidacloprid induces neurobehavioral defi-
cits [16,17]. Imidacloprid kills a variety of insects through
action on the nicotinic receptor [18]. Imidacloprid is used
agriculturally and it is an active ingredient of flea and
tick treatments for household pets [19]. Imidacloprid
was introduced for consumer use in 1999 and usage
has rapidly increased since, but its health effects on
humans are poorly understood [18,19]. The current
analysis examines whether household imidacloprid
usage as a flea and tick treatment on household pets
is associated with ASD using data from a large case–
control study with extensive, maternally-reported infor-
mation on prenatal exposures.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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imidacloprid exposure is characterized by parent report,
we rigorously explore the potential for any observed
associations to be obscured or inflated by systematic
biases due to misclassification of imidacloprid exposure.
In case–control studies, use of retrospectively reported
exposures can be subject recall bias, and overly broad
exposure definitions can attenuate the apparent effects
of etiologically relevant exposures [20]. We apply analytic
methods to address both of these potential sources of
error using frequentist and Bayesian methods to account
for exposure measurement error and we perform several
sensitivity analyses [21,22]. While correcting for exposure
misclassification is possible using frequentist methods,
Bayesian methods were preferable for several reasons.
Practically speaking, our approach was a natural fit for a
Bayesian framework in which we can fit a single (complex)
model rather than piecing together several frequentist
models. In principle, Bayesian methods also allow ex-
plicit inclusion of prior knowledge and can preclude
time-consuming model selection procedures through
stabilization, rather than elimination, of regression model
terms [23].
The aims of the analysis are to 1) estimate associations
between imidacloprid and ASD adjusted for confoun-
ders, but without accounting for exposure misclassifi-
cation (frequentist and Bayesian), 2) utilize restriction
and time-window analysis to estimate associations in
which exposure measurement error may be less severe
(frequentist) and 3) estimate the posterior OR for a




Participants were recruited as part of the ongoing
Childhood Autism Risks from Genetics and Environment
(CHARGE) Study, a population based, case–control inves-
tigation of the environmental and genetic causes of autism
conducted at the UC Davis MIND (Medical Investigations
of Neurodevelopmental Disorders) Institute. Children pre-
viously identified as having ASD are recruited from: an
administrative database of the California Department of
Developmental Services, which contract 21 Regional Cen-
ters to coordinate services for persons with developmental
disabilities; health and service providers; other MIND
Institute research studies; and self-referrals. Regional
Centers are estimated to provide services to 75-80% of all
children with ASD in their catchment areas [24]. General
population controls were recruited from state birth re-
cords, with frequency matching to the age and Regional
Center distribution and the projected sex distribution of
the ASD cases. Further details of the CHARGE Study have
been described elsewhere [25].Outcome
ASD was assessed using the Autism Diagnostic
Interview-Revised and the Autism Diagnostic Observa-
tion Schedules [26,27]. Clinically trained study personnel
determined cognitive function using the Mullen Scales
of Early Learning and adaptive function using the
Vineland Adaptive Behavior Scales and retrospectively
assessed developmental trajectory in all children with
the Child Development Questionnaire (a subset of the
Early Development Questionnaire) [28-30]. The Social
Communications Questionnaire (SCQ) was adminis-
tered to general population controls and those who
screened positive were assessed for autism spectrum dis-
orders [31]. Study personnel assigned a final case status of
ASD based on standard cut-offs for the Autism Diagnostic
Interview-Revised and Autism Diagnostic Observation
Schedules, (e.g. Risi et al. [32]) or typically developing
based on an SCQ score <15 and scoring above the cut-off
of two standard deviations below the mean on tests of
cognitive and adaptive function.
Exposure
Exposure and confounder data were collected through
maternal phone interview from the Environmental
Exposure Questionnaire. Interviewers were trained in
this instrument and were available for English or Spanish
speakers. Household imidacloprid usage was determined
from the response to the question "During the index
time until now, did you or anyone in your household
use sprays, dusts, powders or skin applications for fleas
or ticks on pets?" (‘index period’ was defined as 3
months prior to conception through breastfeeding). This
was followed by identification of which product was
used and when (which months during the period 3
months before conception to birth, and in which years
after birth). Children were considered exposed if their
mother reported use of Advantage and K9 Advantix on
pets, which contain approximately 9% imidacloprid. The
recommended use of the product is monthly application
to pets. We classified exposure as consistent (use at least
once each month during pregnancy) or occasional (used
less than once each month during pregnancy). No other
household products containing imidacloprid were repor-
ted to have been used [18]. We considered a child exposed
prenatally (yes = 1 or no = 0) if the mother reported any
household usage from 3 months before conception until
birth. We also classified exposure as separate binary indi-
cators for the three-month period prior to conception,
each trimester of pregnancy, and each year of the child’s
life, up to age two.
Additional covariates
We created a Directed Acyclic Graph (DAG) to select a
priori covariates for our statistical models based on existing
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[33]. Hypothesized risk factors chosen for control
were on unblocked backdoor paths and not down-
stream from exposure or outcome [34]. Covariates selec-
ted from our DAG were: Maternal education [high school,
college degree (reference), and at least some college], race/
ethnicity [White/non-Hispanic (reference), other], parity
[ordinal integer] and pet ownership during pregnancy
[1 = yes, 0 = no], as well as the matching factors (child’s
sex [male = 0, female = 1] and age at interview [in years,
centered at the mean], and region of birth [indicator vari-
ables, 5 categories]).
Statistical analysis
Associations between imidacloprid and ASD
To address our primary aim, we used Bayesian methods
for logistic regression [21]. Prior estimates for regression
parameters (for maternal education, race, and parity)
were derived from crude estimates provided in five
studies on perinatal risk factors for ASD [35-39]. These
studies were chosen because the study samples were
similar to the CHARGE sample. Regression coefficients
for which we could obtain no valid prior information
(those for the effects of imidacloprid, the matching factors,
pet ownership, and the intercept) were given normally
distributed priors with a mean of 0 and a variance of 10
(N (0,10)). These regression coefficients are reported
in detail in Table 1 of the Additional file 1. This analysis
assumes perfect exposure classification, which we refer to
as our “naïve” model.
To investigate whether the association differs by the
reported timing of exposure, we estimated the OR in
separate models for the three month pre-conception
period, each trimester, and first three years of life. We
performed this analysis using frequentist logistic regres-
sion models because we have little prior knowledge
regarding how to set time-specific misclassification priors,
since these are rarely, if ever, reported in relevant lite-
rature. We also report the results of models stratified by
consistency of imidacloprid use (used throughout the
entire prenatal period, or only used in part of the
prenatal period).
A Bayesian approach to correcting for potential exposure
misclassification
To correct for potential misreporting of exposure by
mothers in CHARGE, we estimated the OR of imida-
cloprid exposure among children with ASD and typically
developing children using a Bayesian approach described
by Gustafson [21] and previously applied by MacLehose
et al. [22]. This method uses 3 jointly estimated models
to simultaneously model the “true” exposure and estimate
its association with ASD. One model was used to model
the probability of the “true” exposure as a function of allcovariates (using N(0,1) prior estimates for model coeffi-
cients) in a logistic model. In the second model we para-
meterize the probability of “true” exposure, given reported
exposure and case/control status, with prior parameter es-
timates of exposure misclassification (sensitivity and false-
positive probability [i.e., 1-specificity]) described below. In
a third model, the probability of a child in the study being
diagnosed with ASD was modeled as a function of the
“true” exposure and all covariates. These probabilities were
then used to estimate the posterior OR of the ASD-
imidacloprid association. As a sensitivity analysis, we exa-
mined the influence of our priors on regression parameters
of the third model by examining posterior estimates de-
rived using vague (~N (0,10), tight (~N (0,1)), and inform-
ative regression parameter priors.
Our model obtains the posterior estimates using
Markov Chain Monte Carlo methods [40], which appro-
ximate the analytic solution to the joint-probability
model for case–control data with misclassified exposures
described by described by Gustafson [21]. Roughly, the
intuition behind this approach is that we use information
on case status (ASD or TD) and exposure probability to
simulate our data under a scenario in which exposure is
reported prospectively, rather than retrospectively (and
thus is not subject to differential misclassification). Using
prior values of sensitivity and specificity, we randomly
select a proportion of exposed and unexposed individuals
(within strata of confounders and the outcome) that
are reclassified with respect to imidacloprid exposure.
The proportion selected for reclassification of expos-
ure is determined by the joint distribution of sensi-
tivity and specificity. These “corrected” data are then
used to model the association between imidacloprid
exposure and ASD. This process is repeated thousands of
times and the results are averaged to obtain the posterior
log-odds ratio.
Because the true extent of exposure misclassification
was unknown, we estimated posterior ORs under a range
of prior misclassification scenarios (i.e. we varied sensitiv-
ity from 70 to 100% and false-positive probability from 0
to 20%) in which we assume that misclassification is
known with certainty (certain misclassification model).
We used 3 levels of priors in our Bayesian analyses:
regression parameter priors on the outcome model (naïve,
certain misclassification models), priors for the misclassifi-
cation model (certain misclassification models), and priors
on the model that estimates the proportion exposed at
each level of the covariates (certain misclassification
models). MacLehose et al. [22] describe the specifics of
these statistical methods in detail.
We report 95% confidence intervals for frequentist
models and 95% credible limits for Bayesian models, and
to reflect precision we calculated Confidence Limit Ratios
(CLR) or Credible Limit Ratios (CrLR), which equal the
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95% limit [41].
All statistical analyses were performed using JAGS
version 3.1 and R version 2.9 with the “R2jags” package
[42]. For Bayesian models we used Markov-Chain Monte
Carlo methods in three chains of 15,000 iterations,
including a 2,000 iteration burn-in and assessed conver-
gence using tests recommended by Gelman and colleagues
[43]. We calculated posterior ORs and 95% credible inter-
vals using the median and the 2.5th and 97.5th percentiles
from the sample of OR estimates.
Results
Demographics
The current analysis includes all CHARGE participants
with clinical interviews, diagnoses, and interview data com-
pleted before September 2011: 587 with confirmed ASD
and 356 confirmed to be typically developing (Table 1).
Typically developing children were slightly younger (mean
3 y 7 mo vs. 3 y 10 mo for ASD). Mothers of children with
ASD had a higher proportion with a college degree (41%
vs. 34%) and were less likely than mothers of typically
developing children to have weekly or more frequent con-
tact with pets during the prenatal period (46% vs. 55%).
Distributions of maternal race/ethnicity and parity
and child’s sex were similar between groups. A negligible
number of participants had missing information for most
covariates.
Report of imidacloprid usage was similar between the
ASD and typically developing groups (20% vs. 21% for
ever use, 12% vs. 11% for prenatal use, Table 1). Mothers
reported that they (rather than other household mem-
bers) applied the insecticide product on the pet in 75%
of the families that reported application.
Imidacloprid-ASD association
Results from the frequentist and naïve Bayesian analyses
(Table 2), assuming perfect exposure classification, indi-
cated an imprecise, weak positive association between
ASD and prenatal imidacloprid exposure compared to
typically developing controls: frequentist adjusted OR
(95% Confidence intervals [CI]) = 1.3 (0.79-2.2); Bayesian
posterior adjusted OR (95% Credible intervals [CrI]) =
1.3 (0.78-2.2). In frequentist models stratified by consis-
tency of use, the OR (95% CI) was 0.69 (0.27-1.8) for
occasional users and 2.0 (1.0-3.9) for consistent users.
As shown in Figure 1, exposure window analysis indi-
cated that the OR was higher for exposures during the
prenatal period than during the first three years of life,
though estimates were imprecise. While a model simul-
taneously adjusting for all exposure periods at once is
more desirable than separate models, the high correl-
ation of usage across the exposure windows precludes
meaningful inference from such a model.We corrected for exposure misclassification under a
range of sensitivity and false-positive probability to pro-
duce posterior ORs for four distinct groups: 1) sensitivity
and false-positive probability assumed greater among
controls; 2) non-differential misclassification; 3) sensitiv-
ity and false-positive probability assumed greater among
cases; 4) sensitivity greater among cases, false-positive
probability is equal between cases and controls. Pos-
terior ORs were highest for group 1, i.e., when exposed
controls were more likely than exposed cases to report
exposure and unexposed controls were more likely to
incorrectly report exposure than unexposed cases, while
groups 3 and 4, in which exposed cases were more likely
than exposed controls to accurately report their expo-
sures, included ORs below one (Figure 2).Sensitivity analyses
Point estimates for a given certain misclassification
scenario differed little according to the type of regres-
sion coefficient prior (informative, vague ~N (0,10), or
tight ~ N (0,1)), except for estimates with the widest confi-
dence intervals (Additional file 1: Figure 1).Discussion
In any case–control study, error in exposure measure-
ment is a potential source of bias, and if measurement
accuracy differs between cases and controls the direction
of bias could be in either direction, depending on the
nature of the errors and how they relate to case–control
status. We show three examples of ways to potentially
mitigate bias from exposure measurement error: 1) re-
strict potentially exposed individuals to those who likely
have most accurate recall (consistent users); 2) examine
exposure-outcome associations both within and outside
of critical windows of susceptibility to examine measure-
ment error induced by including extraneous exposures;
and 3) explicitly correct the OR for potential exposure
misclassification under plausible scenarios. We observed
that, upon restricting exposure to individuals reporting
consistent use of imidacloprid during pregnancy, the
odds of reported imidacloprid exposure among mothers
of children with ASD is twice that of mothers of TD
children. Figure 1 shows that we also observed an in-
crease in the OR during pregnancy versus early postnatal
exposures, consistent with reports of other pesticide-
ASD associations. Over a range of potential misclassifi-
cation scenarios, we observed posterior ORs ranging
from slightly decreased risk (OR ~ 0.6) to strongly in-
creased risk (OR ~ 4.0) for ASD diagnosis with prenatal
imidacloprid exposure. To our knowledge, no previous
authors have reported on associations between imidaclo-
prid and developmental outcomes in humans and, while
bias cannot be completely ruled out, we believe that the






N (%) N (%)
Imidacloprid usage (ever)
No 461 (79) 280 (79)
Yes 115 (20) 75 (21)
Missing 11 (2) 1 (0)
Imidacloprid usage (prenatal)
No 491 (84) 300 (84)
Yes - total 70 (12) 40 (11)
Yes – Consistent† 47 (8) 20 (6)
Yes – Occasional† 15 (3) 14 (4)
Missing 26 (4) 16 (4)
Maternal education
College degree 243 (41) 120 (34)
High school 88 (15) 54 (15)
Some college 256 (44) 182 (51)
Missing 0 (0) 0 (0)
Child’s age at interview
Mean 3.80 3.56
Standard deviation 0.81 0.81
Missing 0 0
Maternal race/ethnicity‡
Asian/Pacific Islander 46 (8) 25 (7)
Black 20 (3) 10 (3)
Multiracial 24 (4) 16 (4)
Native American/Alaskan 3 (1) 1 (0)
Other race 0 (0) 1 (0)
White/Hispanic 140 (24) 69 (19)
White/Non-Hispanic 330 (56) 221 (62)
Missing 24 (4) 13 (4)
Child’s sex
Male 497 (85) 295 (83)
Female 90 (15) 61 (17)
Missing 0 (0) 0 (0)
Parity
Primiparous 160 (27) 99 (28)
2 194 (33) 102 (29)
3 116 (20) 64 (18)
4 59 (10) 50 (14)
>4 51 (9) 38 (11)
Missing 7 (1) 3 (1)
Table 1 Characteristics of study participants in CHARGE
through September 2011 (Continued)
Pet contact (prenatal)
No 168 (29) 97 (27)
Yes 272 (46) 196 (55)
Missing§ 147 (25) 63 (18)
† Consistent = reported imidacloprid use for every month of prenatal period;
Occasional = reported only some months of use during prenatal period.
Frequency is missing if exposure in any month is missing.
‡ Maternal race/ethnicity: single variable combining the two variables: race
and ethnicity. Categories were hierarchical: race was assigned first; then
among whites, was assigned as Hispanic or non-Hispanic.
§ 213 individuals missing prenatal pet contact information resulting from
faulty skip pattern in phone interview software for some participants.
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rants further epidemiologic and biologic investigation.
Imidacloprid was first registered for use as a pesticide
in the US in 1994 and is widely used by pet owners, yet
little work has since been conducted to assess human
health effects. Initial tests for developmental toxicity of
imidacloprid indicated oral dosing of pregnant rats to be
associated with decreased motor activity and decreased
caudate/putamen thickness in offspring (female rats only)
[17]. Abou-Donia et al. noted that prenatally exposed rats
displayed sensorimotor deficits and increased expression
of glial fibrillary acidic protein, which has been previously
reported among persons with ASD [44,45], and in a
mouse model for ASD [46]. Further, the primary action of
imidacloprid on nicotinic-cholinergic receptors is similar
to that of organophosphates [47], which have previously
been associated with ASD [14,15]. Dermal absorption of
imidacloprid can result from petting recently treated
animals [48], but the dose that could potentially reach theTable 2 Bayesian and frequentist logistic regression
results for preferred model comparing the log-odds of
imidacloprid exposure during the prenatal period
OR (95% CI) † CLR‡
Frequentist
Crude 1.1 (0.71, 1.6) 2.3
Matching factors only 1.2 (0.79, 1.8) 2.3
Fully adjusted 1.3 (0.79, 2.2) 2.8
Occasional users vs. unexposed§ 0.69 (0.27, 1.8) 6.6
Consistent users vs. unexposed§ 2.0 (1.0, 3.9) 3.7
Bayesian
Naïve 1.3 (0.78, 2.2) 2.9
† 95% CI – 95% Confidence (frequentist) or Credible (Bayesian) limits
‡ CLR – Confidence or Credible limit ratio = (upper 95% limit/lower 95% limit).
All models were adjusted for child’s sex, regional center of birth, and age,
maternal education, race/ethnicity, and parity and pet ownership during the
prenatal period. Bayesian priors on regression coefficients and misclassification
parameters are described in text.
§ Occasional users: reported imidacloprid use during some, but not all months
of prenatal period; Consistent users: reported imidacloprid use during all






















Figure 1 Adjusted odds ratios and 95% confidence intervals
comparing imidacloprid exposure of children with autism
spectrum disorder with typically developing controls from the
CHARGE data. Estimates are from separate frequentist, unconditional
logistic models for each time period. All models were adjusted for
child’s sex, regional center of birth, and age, maternal education, race/







0.70   0.01      0.99   0.01
0.70   0.00      1.00   0.00
0.70   0.05      1.00   0.05
0.90   0.05      0.95   0.05
0.95   0.01      0.99   0.01
0.77   0.02      0.88   0.05
0.90   0.05      0.95   0.10
0.90   0.02      0.98   0.05
0.90   0.02      0.98   0.10
0.92   0.05      0.95   0.08
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0.95   0.05      0.95   0.05
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0.80   0.05      0.70   0.05
0.95   0.05      0.70   0.05
0.95   0.05      0.90   0.02
0.98   0.05      0.90   0.02
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TD                 ASD
Figure 2 Adjusted odds ratios and 95% confidence intervals compari
disorder (ASD) to that of typically developing (typically developing) c
positive probability (FPP, 1-specificity) priors used in the Bayesian models a
models). Models are broken into four groups; 1: sensitivity and FPP are gre
and controls (non-differential misclassification); 3: sensitivity and FPP are gr
between cases and controls.
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ined potential neurotoxic effects of imidacloprid on the
human fetus. We did not have data on how much physical
contact the mother had with the pet that was treated.
Case control studies utilizing self-report to identify
exposures of interest are prone to differential exposure
misclassification that can lead to bias. The CHARGE
Study utilizes maternal recall of household pesticide use
from, on average, 4 years in the past; independent assess-
ment of household pesticide exposures was not feasible.
Bayesian methods to correct for exposure misclassification
can sometimes circumvent these shortcomings, but the
results are sensitive to assumptions about the magnitude
and precision of misclassification of the exposure.
As shown in Table 2, adjusted frequentist models and
naïve Bayesian models agree that there is no appreciable
difference in exposure between children with ASD and
TD children, providing remarkably similar point estimates
and precision. An elevated risk associated with exposure
is, nevertheless, suggested by the susceptibility window
analysis in Figure 1, and the doubling of odds for con-
sistent users of imidacloprid-containing pet products. In
addition to signifying a possible etiologic relationship, this
elevation in reported imidacloprid use during pregnancy
is also consistent with a) a mitigating factors such as small
sample size or bias due to confounding or b) recall bias
arising from (for example) concerns about prenatal expo-
sures in which improved reporting or over-reporting of(95% CI)
1.5 2.0 3.0 4.0 6.0
ng imidacloprid exposure of all children with an autism spectrum
ontrols. This sensitivity analysis varies sensitivity (Sens) and false
ssuming known exposure misclassification (certain misclassification
ater among controls; 2: sensitivity and FPP are equal between cases
eater among cases; 4: sensitivity greater among cases, FPP is equal
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the prenatal period but is lower in early life.
Any interpretation of our results must be tempered by
the following caveats: a) our initial assumptions about
how the magnitude of misclassification differs between
case and control mothers may not be plausible (which
warrants estimation of the OR under multiple scenarios)
b) the apparently higher ORs for exposure during preg-
nancy or among consistent users could also be consistent
with recall bias if sensitivity and specificity of recall varied
over time or if mothers of children with ASD dispropor-
tionately report consistent (rather than occasional) use,
and c) imprecision in the posterior ORs indicates that they
are derived from relatively small numbers of individuals in
some strata. Because of these caveats, caution is warranted
in interpreting our elevated ORs as indicative of a true
association – other studies could build on our results by
estimating misclassification parameters across time, by
prospectively assessing exposure, or by focusing on popu-
lations with a higher proportion of households using this
pesticide (such as pet owners).
The analysis shown in Figure 2 indicates that, in mis-
classification models, small changes in the false-positive
probability estimate for children with ASD can lead to dis-
proportionately large changes in the posterior OR, which
has also been observed by Marshall [50] and Gustafson
and colleagues [21]. A priori, one might expect that sensi-
tivity and false-positive probability would both be higher
among mothers of children with ASD (group 3 in Figure 2),
resulting in upward bias. Higher reporting of exposure
among mothers of TD children (and the highest observed
ORs - group 1) seems most implausible. Our susceptibility
window analysis and the analysis in which exposure is
stratified by consistency of reported use suggest the possi-
bility that exposure misclassification could be obscuring,
rather than enhancing, an association between ASD and
imicloprid. If this were the case, the summary OR of the
adjusted frequentist model and the naïve Bayesian analysis
may be a) biased because of exposure misclassification due
to inaccurate reporting or b) a poor estimate of an etiologic
relationship due either to a classification scheme in which
potentially biologically relevant exposure (i.e. high exposed
groups or exposure during neurogenesis) is lumped
with less relevant exposure. An analysis by Roberts
et al. suggests that there may be a critical window in early
pregnancy during which exposure to organophosphate
pesticides may magnify risk for development of ASD [14].
The trade-off of focusing on subgroups or specific win-
dows of exposure is a loss of precision in estimating an
association; hence, we used multiple approaches to ad-
dress exposure misclassification.
Our findings underscore the need for validation stud-
ies of maternal self-report of household exposures in
studies of childhood behavioral and neurologic disorders.Because we were unable to place informative central
estimates on sensitivity and specificity of imidacloprid
report during the prenatal period, we can provide only
posterior ORs under a range of plausible estimates. If
the posterior ORs in Figure 2 indicated a consistent
direction of association between imidacloprid and ASD,
there would be little concern that inaccurate recall of
exposure could be masking a true association. Unfortu-
nately, such validation studies have yet to be conducted.
One area in which such studies have been conducted is in
regard to prenatal cigarette smoking and birth defects,
likely due to the ready availability of a valid biomarker of
exposure (cotinine) and the short follow-up time neces-
sary to evaluate health outcomes in newborns. MacLehose
et al. [22] applied Bayesian methods for exposure mis-
classification to an analysis of maternal smoking and
orofacial clefts. The authors observed a 20% increase
in the posterior OR for the prenatal smoking-cleft lip/pal-
ate association after correcting for misclassification and
allowing for sampling error in the sensitivity and false-
positive probability estimates. In a study of smoking and
invasive pneumococcal disease, Chu et al. [51] applied a
Bayesian analysis under a range of sensitivity and false-
positive probability values similar to ours, though the
authors allowed for both for uncertainty in the misclassifi-
cation parameters as well as correlation between sen-
sitivity and false-positive probability, which we did not do.
In the case of both MacLehose et al. and Chu et al., the
authors had a range of prior validity studies with validated
biomarkers to inform the sensitivity analysis and poten-
tially allow estimation of a central, posterior OR. Were
that information available to us, our 95% posterior credible
intervals could more accurately account for uncertainty
about sensitivity and false-positive probability. Bayesian
analysis allows explicit incorporation of prior infor-
mation, which is a relative strength compared to our
other methods of dealing with exposure misclassification.
While biomarkers have been developed for maternal
exposures to certain pesticides, much work remains to
be done in this field [5], and the delay between birth and
the diagnosis of ASD is problematic both for maternal
recall as well as for establishing correlations between
biomarker levels after diagnosis with prenatal exposures.
One potential pitfall is that a given biomarker may not ne-
cessarily isolate a single exposure, since several pesticides
may result in indistinguishable metabolic byproducts [5].
In our analysis of CHARGE data, adjustment for exposure
to pyrethroids (~31% reported use), another household
pesticide often used in flea and tick products for pets,
changed the OR by less than 5%, as did restricting our
analysis to pet owners (not shown).
Because imidacloprid effects on human development
are not well understood, we were unable to place an
informative prior estimate on the OR for imidacloprid
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cation models likely overestimates the effect that slight
changes in sensitivity and false-positive probability esti-
mates would have on the posterior OR for exposures
with extensive prior literature. For example, parental
autoimmune disease associations with ASD have been
well-studied [52-55], so a posterior OR for autoimmune
disease-ASD associations would show less variation across
sensitivity and false-positive probability estimates than is
observed in the current study due to an informative prior.
Thus, the variation in ORs across misclassification param-
eters (Figure 2) would be smaller in association studies of
more well-researched risk factors in autism. Additionally,
our lack of informative prior on the OR for imidacloprid
exposure also contributed to the similarity between the
naïve Bayesian analysis and the frequentist analysis, and,
in this case, the advantages of the naïve Bayesian over the
frequentist analysis are mainly theoretical. The difference
would have been more pronounced had we either a) been
able to provide and informative prior on the OR for
imidacloprid use or b) included some confounders that re-
sult in empty strata, in which case the frequentist model
may not have converged or would have reduced precision
of the OR estimate.
We considered the potential for recently reported vari-
ability in ASD risk associated with season and vitamin use
to impact our results [56-58]. Imidacloprid usage patterns
did not vary by season and in frequentist logistic models
with additional adjustment for winter birth (January-
March) the log-odds ratio for imidacloprid exposures
(consistent and occasional use) changed by less than 1%
(not shown). Adjustment for prenatal vitamin use changed
the log-odds ratio by less than 3% (not shown).
Little is known about the causes of ASD, so uncon-
trolled confounding or selection bias cannot be ruled out
[59]. The CHARGE study collected vast amounts of infor-
mation on potential covariates from multiple sources,
allowing for a potential reduction in confounding or selec-
tion bias that may be present in larger, records-based
studies that cannot collect detailed data at the individual
level. In spite of the stated shortcomings, the current ana-
lysis represents a thorough examination of the association
between a household pesticide and subsequent ASD diag-
nosis that addresses potentially differential misclassifi-
cation of exposure, thereby overcoming a major challenge
in case–control studies when persistent biomarkers for
exposure have not been identified.
Ultimately, we do not currently know the true distri-
bution of imidacloprid exposure in the CHARGE study,
and we also do not know how closely applications of flea
and tick products to household pets correlates with fetal
exposure. We did not address imidacloprid exposure
from food or from residential proximity to commercial
spraying, nor did we distinguish genetically susceptiblecase subgroups, who may have different associations
with environmental exposures.
Conclusions
Our findings highlight the need for validation studies of
exposures in different time intervals. Future large cohorts
(e.g. the National Children’s Study [60]) have an opportun-
ity to improve on the exposure misclassification estimates
by collecting both prospective and retrospective informa-
tion on pesticide exposures. Analyses similar to ours will
benefit from reporting of sensitivity and specificity esti-
mates of household product use based on comparisons of
retrospective reporting relative to prenatal reporting or
biomarker measurements that accurately reflect prenatal
exposures. Links between imidacloprid and developmental
outcomes in animal studies, the potential for exposure from
household or nearby agriculture applications, and the re-
sults shown in frequentist analyses and in Bayesian models
with misclassification-corrected models for some scenarios
provide hints that this association warrants further study.
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